Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celsion Could File ThermoDox Doxorubicin Delivery System For Liver Cancer By 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

Company’s proprietary heat-sensitive liposome could provide drug delivery for several cancer types, CEO Tardugno tells “The Pink Sheet” DAILY.

You may also be interested in...



Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.

Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.

Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.

Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.

China State FDA Grants Clinical Trial Approval For Celsion's Phase III Liver Cancer Trials

SHANGHAI - China's State FDA granted clinical trial approval to Columbia, Md.-based Celsion to conduct Phase III trials in China as part of the company's global trial program for leading product ThermoDo.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel